Читать книгу Biologics, Biosimilars, and Biobetters - Группа авторов - Страница 91

Neulasta^® is pegylated version of Neupogen^® launched by Amgen in 2002, with extended half‐life, which allows for administration as a single dose per chemotherapy cycle compared with daily dosing with Amgen's Neupogen^®, for reducing the incidence of infection, as manifested by febrile neutropenia in patients with nonmyeloid malignancies who are receiving myelosuppressive drugs.

Indication: Neutropenia related to cancer chemotherapy

Manufacturer: Amgen

Global Sales in 2017: US$4.7 billion

Generic name: Pegfilgrastim

Launch date: 2002